miun.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
A minimum protocol for randomised homeopathic drug proving as basis for further research.
Mittuniversitetet, Fakulteten för humanvetenskap, Avdelningen för omvårdnad. European Comm Homeopathy, Subcomm Provings, Groningen, Netherlands.
Mittuniversitetet, Fakulteten för humanvetenskap, Avdelningen för omvårdnad.ORCID-id: 0000-0002-3907-2197
Mittuniversitetet, Fakulteten för humanvetenskap, Avdelningen för omvårdnad.ORCID-id: 0000-0001-6985-6729
Mittuniversitetet, Fakulteten för humanvetenskap, Avdelningen för omvårdnad. Louis Bolk Inst, Dept Hlth & Nutr, Driebergen, Netherlands.
2014 (Engelska)Ingår i: Forschende Komplementärmedizin, ISSN 1661-4119, E-ISSN 1661-4127, Vol. 21, nr 4, s. 232-8Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

BACKGROUND: In order to further improve the methodology and quality of data collection in homeopathic drug provings (HDP), there is a need for a minimum standardised HDP protocol. The objective of the present study was to test the feasibility of this type of protocol.

MATERIALS AND METHODS: The study protocol embraced a multi-centre, randomised, double-blind, placebo-controlled trial with 2 parallel groups. It was approved by an ethics review committee. During the pre-approval phase, discordances between the regulatory and homeopathic requirements for the protocol were checked and solutions found. The study medication was Potentilla anserina. 6 participants received verum and 4 placebo. The resulting symptom list will be published elsewhere. The procedure was accepted by all participants.

RESULTS: Three important issues were addressed: the requirement to keep all participants blinded; the adverse events reporting to regulatory authorities; and the necessity of a placebo control group. Other issues that need further investigations were identified, e.g. sample size, observation period and dosage regimen.

CONCLUSIONS: A minimum protocol of a HDP is feasible. All important design elements of HDP could be solved in discussions with the respective regulatory authorities, and participating homeopaths accepted the procedure.

Ort, förlag, år, upplaga, sidor
2014. Vol. 21, nr 4, s. 232-8
Nyckelord [en]
Blinding, Data collection, Materia Medica, Minimum trial protocol, Placebo control, Serious adverse events, Report
Nationell ämneskategori
Hälsovetenskaper
Identifikatorer
URN: urn:nbn:se:miun:diva-23497DOI: 10.1159/000366042ISI: 000345833700004PubMedID: 25231564Scopus ID: 2-s2.0-84927734205OAI: oai:DiVA.org:miun-23497DiVA, id: diva2:766428
Tillgänglig från: 2014-11-27 Skapad: 2014-11-27 Senast uppdaterad: 2017-12-05Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMedScopus

Personposter BETA

Jansen, Jean PierreJong, MatsHildingsson, IngegerdJong, Miek C

Sök vidare i DiVA

Av författaren/redaktören
Jansen, Jean PierreJong, MatsHildingsson, IngegerdJong, Miek C
Av organisationen
Avdelningen för omvårdnad
I samma tidskrift
Forschende Komplementärmedizin
Hälsovetenskaper

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 266 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf